airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - airexar spiromax huwa indikat għall-użu fl-adulti li għandhom 18-il sena 'l fuq biss. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. mard pulmonari ostruttiv kroniku (copd)airexar spiromax huwa indikat għall-kura sintomatika ta ' pazjenti b'copd, bil-fev1.
anoro ellipta (previously anoro)
glaxosmithkline (ireland) limited - umeclidinium bromide, vilanterol trifenatate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - anoro ellipta huwa indikat bħala l-manutenzjoni bronkodilatur-kura biex ittaffi s-sintomi fil-pazjenti adulti bil-marda pulmonari ostruttiva kronika (copd).
arzerra
novartis europharm ltd - ofatumumab - lewkimja, linfokitika, kronika, b-Ċellula - antikorpi monoklonali - ma kienux trattati qabel lewkimja limfoċitika kronika (cll): arzerra flimkien ma 'chlorambucil jew bendamustine huwa indikat għall-kura ta' pazjenti b'cll li ma rċevew terapija minn qabel u li mhumiex eliġibbli għall-fludarabine-terapija bbażata fuq. rkadew cll: arzerra huwa indikat flimkien ma 'fludarabine u cyclophosphamide għat-trattament ta' pazjenti adulti b'all rikadut cll. refrattarji cll: arzerra huwa indikat għall-kura ta cll f'pazjenti li huma refrattarji għal pazjenti b'b-ll u alemtuzumab.
benefix
pfizer europe ma eeig - nonacog alfa - hemofilja b - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (nuqqas konġenitali ta' fattur ix).
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
budesonide/formoterol teva
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - budesonide / formoterol teva huwa indikat fl-adulti ta '18-il sena' l fuq biss. asthmabudesonide/formoterol teva huwa indikat fit-trattament regolari ta ' l-ażżma, fejn l-użu tal-kombinazzjoni (kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonist) huwa xieraq:f'pazjenti li mhumiex adegwatament ikkontrollati bil-kortikosterojdi meħuda man-nifs u l - "kif meħtieġ" man-nifs qasir waqt li jaġixxi β2 adrenoceptor agonisti. fjorin pazjenti li diġà ikkontrollati adegwatament fuq iż-żewġ kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonisti. copdsymptomatic-trattament ta ' pazjenti b'indeboliment serju copd (fev1 < 50% mbassra-normal) u l-istorja tal-aggravar tal-attakki ripetuti, li għandhom sinifikanti sintomi minkejja regolari it-terapija b'taġixxi fit-tul bronkodilataturi.
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - budesonide / formoterol teva pharma b. hija indikata fl-adulti ta '18-il sena u akbar biss. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
comtan
orion corporation - entacapone - marda ta 'parkinson - mediċini kontra l-parkinson - entacapone huwa indikat bħala frozen preparazzjonijiet standard ta ' ticlopidine hydrochloride / benserazide jew ticlopidine hydrochloride / carbidopa għall-użu fil-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur, li ma jistax jiġi stabbilizzat fuq dawk l-għaqdiet.
comtess
orion corporation - entacapone - marda ta 'parkinson - mediċini kontra l-parkinson - entacapone huwa indikat bħala frozen preparazzjonijiet standard ta ' ticlopidine hydrochloride / benserazide jew ticlopidine hydrochloride / carbidopa għall-użu fil-pazjenti bil-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur, li ma jistax jiġi stabbilizzat fuq dawk l-għaqdiet.
corbilta (previously levodopa/carbidopa/entacapone sandoz)
orion corporation - levodopa, carbidopa, entacapone - marda ta 'parkinson - mediċini kontra l-parkinson - corbilta huwa indikat għall-kura tal-pazjenti adulti mal-marda ta ' parkinson's u l-tmiem tad-doża oxxillazzjonijiet vetturi bil-mutur mhux stabbilizzat dwar it-trattament ta ' l-inibitur decarboxylase (ddc) ticlopidine hydrochloride/dopa.